Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. more
Time Frame | GLSI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.23% | -3.72% | -0.05% |
1-Month Return | 4.28% | -1.85% | 2.75% |
3-Month Return | -10.66% | -11.4% | 7.4% |
6-Month Return | -26.03% | -4.41% | 10.47% |
1-Year Return | 26.97% | 4.13% | 27.57% |
3-Year Return | -52.29% | 0.3% | 29.56% |
5-Year Return | 158% | 36.62% | 89.3% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | [{"date":"2019-12-31","value":99.86,"profit":true},{"date":"2020-12-31","value":99.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (3.61K) | [{"date":"2019-12-31","value":-360700,"profit":false},{"date":"2020-12-31","value":-360900,"profit":false},{"date":"2021-12-31","value":-361200,"profit":false},{"date":"2022-12-31","value":-361200,"profit":false},{"date":"2023-12-31","value":-361200,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 3.43M | 1.86M | 4.60M | 8.04M | 9.33M | [{"date":"2019-12-31","value":36.72,"profit":true},{"date":"2020-12-31","value":19.98,"profit":true},{"date":"2021-12-31","value":49.29,"profit":true},{"date":"2022-12-31","value":86.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (3.43M) | (1.86M) | (4.60M) | (8.04M) | (9.33M) | [{"date":"2019-12-31","value":-342530700,"profit":false},{"date":"2020-12-31","value":-186379400,"profit":false},{"date":"2021-12-31","value":-459794300,"profit":false},{"date":"2022-12-31","value":-804025400,"profit":false},{"date":"2023-12-31","value":-932786600,"profit":false}] |
Total Non-Operating Income/Expense | - | 1.66K | 54.73K | 430.03K | 887.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.19,"profit":true},{"date":"2021-12-31","value":6.17,"profit":true},{"date":"2022-12-31","value":48.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (3.43M) | (1.86M) | (4.57M) | (7.83M) | (8.89M) | [{"date":"2019-12-31","value":-342530700,"profit":false},{"date":"2020-12-31","value":-186296200,"profit":false},{"date":"2021-12-31","value":-457057600,"profit":false},{"date":"2022-12-31","value":-782523700,"profit":false},{"date":"2023-12-31","value":-889180300,"profit":false}] |
Income Taxes | 3.00 | (832.00) | (27.37K) | (215.02K) | (2.00) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-27733.33,"profit":false},{"date":"2021-12-31","value":-912233.33,"profit":false},{"date":"2022-12-31","value":-7167233.33,"profit":false},{"date":"2023-12-31","value":-66.67,"profit":false}] |
Income After Taxes | - | (1.86M) | (4.54M) | (7.61M) | (8.89M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-186213000,"profit":false},{"date":"2021-12-31","value":-454320900,"profit":false},{"date":"2022-12-31","value":-761022000,"profit":false},{"date":"2023-12-31","value":-889180100,"profit":false}] |
Income From Continuous Operations | (3.43M) | (1.86M) | (4.57M) | (7.83M) | (8.94M) | [{"date":"2019-12-31","value":-342530700,"profit":false},{"date":"2020-12-31","value":-186296200,"profit":false},{"date":"2021-12-31","value":-457057600,"profit":false},{"date":"2022-12-31","value":-782523700,"profit":false},{"date":"2023-12-31","value":-893557600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.43M) | (1.86M) | (4.54M) | (7.61M) | (8.89M) | [{"date":"2019-12-31","value":-342530700,"profit":false},{"date":"2020-12-31","value":-186213000,"profit":false},{"date":"2021-12-31","value":-454320900,"profit":false},{"date":"2022-12-31","value":-761022000,"profit":false},{"date":"2023-12-31","value":-889180300,"profit":false}] |
EPS (Diluted) | (14.25) | (0.20) | (0.36) | (0.61) | (0.69) | [{"date":"2019-12-31","value":-1424.96,"profit":false},{"date":"2020-12-31","value":-20,"profit":false},{"date":"2021-12-31","value":-36,"profit":false},{"date":"2022-12-31","value":-61,"profit":false},{"date":"2023-12-31","value":-69,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GLSI | |
---|---|
Cash Ratio | 6.91 |
Current Ratio | 6.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GLSI | |
---|---|
ROA (LTM) | -72.45% |
ROE (LTM) | -123.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GLSI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GLSI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 35.64 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Greenwich Lifesciences Inc (GLSI) share price today is $12.9
Yes, Indians can buy shares of Greenwich Lifesciences Inc (GLSI) on Vested. To buy Greenwich Lifesciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLSI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Greenwich Lifesciences Inc (GLSI) via the Vested app. You can start investing in Greenwich Lifesciences Inc (GLSI) with a minimum investment of $1.
You can invest in shares of Greenwich Lifesciences Inc (GLSI) via Vested in three simple steps:
The 52-week high price of Greenwich Lifesciences Inc (GLSI) is $21.44. The 52-week low price of Greenwich Lifesciences Inc (GLSI) is $8.
The price-to-earnings (P/E) ratio of Greenwich Lifesciences Inc (GLSI) is
The price-to-book (P/B) ratio of Greenwich Lifesciences Inc (GLSI) is 35.64
The dividend yield of Greenwich Lifesciences Inc (GLSI) is 0.00%
The market capitalization of Greenwich Lifesciences Inc (GLSI) is $177.58M
The stock symbol (or ticker) of Greenwich Lifesciences Inc is GLSI